GRAIL Investors May Lead Securities Fraud Lawsuit
Purchasers of GRAIL, Inc. common stock between May 13, 2025, and February 19, 2026, are being notified of the opportunity to serve as lead plaintiff in a securities fraud class action lawsuit.
Rosen Law Firm, an international investor rights law firm, has announced that purchasers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, inclusive, have the opportunity to lead a class action lawsuit.
The lawsuit alleges that GRAIL's management issued misleading statements regarding the results of the company's NHS-Galleri trial. The complaint claims that defendants provided overly positive statements while allegedly concealing material adverse facts about the trial's effectiveness in demonstrating a reduction in Stage III-IV cancers. It is alleged that the trial period was insufficient to prove the primary endpoint was achievable.
Investors who bought GRAIL stock during the specified period must file a motion with the Court by August 4, 2026, to be considered for the lead plaintiff role. The lead plaintiff acts as a representative party for other class members in directing the litigation. Rosen Law Firm emphasizes the importance of selecting experienced counsel with a proven track record in securities class actions.
Further details regarding the class action and how to join are available on the Rosen Law Firm website or by contacting Phillip Kim, Esq. No class has yet been certified in the action.